Preclinical drug development must consider the impact on metastasis
Steeg, Patricia S., Anderson, Robin L., Bar-Eli, Menashe, Chambers, Ann F., Eccles, Suzanne A., Hunter, Kent W., Itoh, Kazuyuki, Kang, Yibin, Matrisian, Lynn M., Sleeman, Jonathan P., Theodorescu, Dan, Thompson, Erik W., & Welch, Danny R. (2009) Preclinical drug development must consider the impact on metastasis. Clinical Cancer Research, 15(14), pp. 4529-4530.
Recently, two landmark reports on antiangiogenic therapy were published: Paez-Ribes and colleagues and Ebos and colleagues . The Board of the Metastasis Research Society (MRS) congratulates the authors for their informative articles that help to explain the puzzle of why antiangiogenic agents have had a relatively minor or no significant impact on patient survival. Using four model systems and several different strategies, these researchers showed that inhibition of angiogenesis reduced primary tumor growth and microvessel density in keeping with many earlier reports, but strikingly, accelerated invasion and metastasis.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
Articles free to read on journal website after 12 months
Cited By (since 1996):19
|Divisions:||Current > QUT Faculties and Divisions > Faculty of Health|
|Deposited On:||29 May 2014 01:50|
|Last Modified:||29 Jan 2015 05:13|
Repository Staff Only: item control page